Paranasal Sinus Squamous Cell Carcinoma Recruiting Phase 1 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0050196 (Paranasal Sinus Squamous Cell Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03381183IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell CarcinomaTreatment